Literature DB >> 25139097

Role of novel and GWAS originated PLCE1 genetic variants in susceptibility and prognosis of esophageal cancer patients in northern Indian population.

Meenakshi Umar1, Rohit Upadhyay, Shaleen Kumar, Uday Chand Ghoshal, Balraj Mittal.   

Abstract

Recent genome-wide association studies (GWAS) have identified variants in phospholipase C epsilon1 (PLCE1) as novel susceptibility markers for esophageal squamous cell carcinoma (ESCC) in Chinese population. Although few studies have replicated this findings in other populations, but results are contradictory. So, we aimed to replicate association of two previously reported non-synonymous polymorphisms (rs2274223A>G and rs3765524C>T) from haplotype block 10 and evaluated a novel variant (rs7922612C>T) from haplotype block 2 of PLCE1 with susceptibility and prognosis of ESCC in northern Indian population. The genotyping of PLCE1 variants were performed in 293 histopathologically confirmed incident ESCC cases (including 177 follow-up cases) and 314 age-, gender-, and ethnicity-matched controls using PCR RFLP. All statistical analyses were performed through SPSS version 15.0. Modeling and functional prediction of two non-synonymous variants were carried out using bioinformatics tools. PLCE1 polymorphisms were not associated with susceptibility to ESCC or its clinical phenotypes (tumor location/lymph node metastasis). No interaction with environmental risk factors was found. In silico analysis suggested negligible effect on structure of PLCE1 protein due to PLCE1 rs2274223 (H1927R) and rs3765524 (T1777I) polymorphisms. Survival analysis showed PLCE1 rs7922612CT + TT genotype conferred adverse outcome to ESCC patients. Our study for the first time suggests that GWAS originated PLCE1 variants do not have independent role in susceptibility of ESCC in northern Indian population; however, a novel haplo-tagging SNP rs7922612 may modify survival outcome of ESCC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139097     DOI: 10.1007/s13277-014-2458-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

Review 1.  Genetic polymorphisms and esophageal cancer risk.

Authors:  Toru Hiyama; Masaharu Yoshihara; Shinji Tanaka; Kazuaki Chayama
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

2.  Evaluation of comparative protein modeling by MODELLER.

Authors:  A Sali; L Potterton; F Yuan; H van Vlijmen; M Karplus
Journal:  Proteins       Date:  1995-11

3.  RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line.

Authors:  Liping Ou; Yongcan Guo; Chunli Luo; Xiaohou Wu; Yi Zhao; Xiaozhong Cai
Journal:  Cancer Genet Cytogenet       Date:  2010-07-15

4.  Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations.

Authors:  Haichuan Hu; Jingmin Yang; Yihua Sun; Yajun Yang; Ji Qian; Li Jin; Mengyun Wang; Rui Bi; Ruoxin Zhang; Meiling Zhu; Menghong Sun; Hongxia Ma; Qingyi Wei; Guoliang Jiang; Xiaoyan Zhou; Haiquan Chen
Journal:  Ann Surg Oncol       Date:  2011-12-28       Impact factor: 5.344

5.  Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer.

Authors:  Xiaoliang Wang; Chongzhi Zhou; Guoqiang Qiu; Yinxue Yang; Dongwang Yan; Tonghai Xing; Junwei Fan; Huamei Tang; Zhihai Peng
Journal:  Med Oncol       Date:  2011-06-11       Impact factor: 3.064

6.  Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations.

Authors:  Chen Wu; Zhibin Hu; Zhonghu He; Weihua Jia; Feng Wang; Yifeng Zhou; Zhihua Liu; Qimin Zhan; Yu Liu; Dianke Yu; Kan Zhai; Jiang Chang; Yan Qiao; Guangfu Jin; Zhe Liu; Yuanyuan Shen; Chuanhai Guo; Jianhua Fu; Xiaoping Miao; Wen Tan; Hongbing Shen; Yang Ke; Yixin Zeng; Tangchun Wu; Dongxin Lin
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

7.  Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.

Authors:  Lilly Y W Bourguignon; Eli Gilad; Amy Brightman; Falko Diedrich; Patrick Singleton
Journal:  J Biol Chem       Date:  2006-03-24       Impact factor: 5.157

Review 8.  The molecular mechanisms of oesophageal cancer.

Authors:  M L McCabe; Z Dlamini
Journal:  Int Immunopharmacol       Date:  2004-12-24       Impact factor: 4.932

9.  Evaluation of MTHFR677C>T polymorphism in prediction and prognosis of esophageal squamous cell carcinoma: a case-control study in a northern Indian population.

Authors:  Meenakshi Umar; Rohit Upadhyay; Rohini Khurana; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

10.  Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.

Authors:  Meenu Jain; Shaleen Kumar; Rohit Upadhyay; Puneeta Lal; Anu Tiwari; Uday C Ghoshal; Balraj Mittal
Journal:  Cancer Biol Ther       Date:  2007-07-07       Impact factor: 4.742

View more
  3 in total

1.  Phospholipase C ε-1 gene polymorphisms and prognosis of esophageal cancer patients from a high-incidence region in northern China.

Authors:  Rong-Miao Zhou; Yan Li; Na Wang; Xi Huang; Shi-Ru Cao
Journal:  Mol Clin Oncol       Date:  2017-10-27

2.  Associations of genetic variants in the PSCA, MUC1 and PLCE1 genes with stomach cancer susceptibility in a Chinese population.

Authors:  Hongwei Sun; Xiaoli Wu; Fang Wu; Ying Li; Zhengping Yu; Xiangrong Chen; Yunzhi Chen; Wenjun Yang
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

3.  PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Guangzhi Zhu; Tingdong Yu; Sicong Lu; Hao Su; Zhen Liu; Zhiwei Chen; Chengkun Yang; Ketuan Huang; Zhengtao Liu; Yu Liang; Jianlu Huang; Jiahong Dong; Lequn Li; Xue Qin; Xinping Ye; Kaiyin Xiao; Minhao Peng; Tao Peng
Journal:  Oncotarget       Date:  2017-04-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.